Cariprazine in Bipolar Depression and Mania: State of the Art

Marianna Mazza, Giuseppe Marano, Gianandrea Traversi, Valentina Carocci, Benedetta Romano, Luigi Janiri

Research output: Contribution to journalArticle

Abstract

BACKGROUND & OBJECTIVE: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.

RESULTS & CONCLUSION: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.

Original languageEnglish
Pages (from-to)723-727
Number of pages5
JournalCNS and Neurological Disorders - Drug Targets
Volume17
Issue number10
DOIs
Publication statusPublished - 2018

Fingerprint

Bipolar Disorder
Dopamine D3 Receptors
Pharmacogenetics
Antipsychotic Agents
Schizophrenia
Randomized Controlled Trials
Pharmacokinetics
Placebos
cariprazine
Clinical Trials
Pharmacology
Safety
Therapeutics

Cite this

Cariprazine in Bipolar Depression and Mania : State of the Art. / Mazza, Marianna; Marano, Giuseppe; Traversi, Gianandrea; Carocci, Valentina; Romano, Benedetta; Janiri, Luigi.

In: CNS and Neurological Disorders - Drug Targets, Vol. 17, No. 10, 2018, p. 723-727.

Research output: Contribution to journalArticle

Mazza, Marianna ; Marano, Giuseppe ; Traversi, Gianandrea ; Carocci, Valentina ; Romano, Benedetta ; Janiri, Luigi. / Cariprazine in Bipolar Depression and Mania : State of the Art. In: CNS and Neurological Disorders - Drug Targets. 2018 ; Vol. 17, No. 10. pp. 723-727.
@article{98917a608d7041c89522b0f7f5b46281,
title = "Cariprazine in Bipolar Depression and Mania: State of the Art",
abstract = "BACKGROUND & OBJECTIVE: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.RESULTS & CONCLUSION: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.",
author = "Marianna Mazza and Giuseppe Marano and Gianandrea Traversi and Valentina Carocci and Benedetta Romano and Luigi Janiri",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
doi = "10.2174/1871527317666180828120256",
language = "English",
volume = "17",
pages = "723--727",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Cariprazine in Bipolar Depression and Mania

T2 - State of the Art

AU - Mazza, Marianna

AU - Marano, Giuseppe

AU - Traversi, Gianandrea

AU - Carocci, Valentina

AU - Romano, Benedetta

AU - Janiri, Luigi

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018

Y1 - 2018

N2 - BACKGROUND & OBJECTIVE: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.RESULTS & CONCLUSION: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.

AB - BACKGROUND & OBJECTIVE: Cariprazine is a piprazine derivative approved by the FDA in 2015 for the treatment of schizophrenia and bipolar manic or mixed episodes in adults. High affinity for D3 dopamine receptors and observed actions on 5HT1A, 5HT2A and alpha 1B receptors differentiate it pharmacologically from other antipsychotics. This review is a comprehensive and thorough summary of the most important findings on cariprazine use in bipolar mania and depression. Pharmacokinetics, pharmacogenetics, tolerability and safety adverse effects are discussed in this paper.RESULTS & CONCLUSION: Moreover, the results from pivotal clinical trials are presented. Cariprazine represents an additional option for clinicians to treat patients with bipolar disorder. It shows a unique pharmacological profile and has demonstrated in randomized clinical trials efficacy and general tolerability compared to placebo in bipolar mania and seem to be a promising therapeutic option for bipolar depression.

U2 - 10.2174/1871527317666180828120256

DO - 10.2174/1871527317666180828120256

M3 - Article

C2 - 30152291

VL - 17

SP - 723

EP - 727

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 10

ER -